20.03.23 Genetic treatments: mutation specific therapy Flashcards

1
Q

What are antisense oligonucleotides (ASOs)

A

-Small single stranded DNA or RNA molecules (~20bp)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What stops ASOs from being degraded by nucleases

A
  • Chemical modifications

- Most common are 2-O-methyl RNA phosphorothioate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Mechanisms of ASOs

A
  • Blockage of cryptic splicing
  • Alternative splicing
  • Exon inclusion
  • Exon skipping
  • Alter transcript translation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How are ASOs used to block cryptic splicing

A

-Beta-thalassemia is caused by mutations in beta-globin gene which activate cryptic splice sites.
2-O-methyl RNA ASOs block access of the spliceosome to these sites enabling normal beta-globin splicing and normal haemoglobin expression.
-Only transient
-ASO needed for each type of mutation (generate, validate, trial). Increases costs and time for production.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How are ASOs used to skip exons

A
  • DMD deletions and duplications can disrupt ORF and cause loss of protein expression. Leads to severe duchenne phenotype. Dels/dups that don’t disrupt ORF cause milder Becker phenotype.
  • ASOs used to mask specific exons to restore ORF and partial dystrophin function.
  • Transient. Low efficacy in heart tissue (many DMD patients die due to heart complications)
  • Due to mutation hotspots, skipping of a small number of exons is applicable to a large number of patients.
  • E.g. exon 51 skipping is used for 14% of DMD cases. Drisapersen
  • New class of ASOs tricyclo-DNA (tcDNA) have improved tissue uptake.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How are ASOs used to cause alternate splicing

A
  • Exon skipping of exon 27 in APOB leads to a reduction in LDL particle secretion and an increase in LDL affinity to LDL receptor
  • LMNA missense mutation shifts alternative splicing, increasing production of truncated lamin A known as progerin. Accumulation of progerin causes Hutchinson-Gilford progeria (HGPS). Patients have accelerated aging and a shortened lifespan. ASO masks splice site restoring normal splicing.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How are ASOs used to enhance splicing

A
  • SMA is caused by deletions of SMN1.
  • SMN2 exon 7 is often skipped due to a C>T transition.
  • Spinraza is an ASO that blocks the ISS (intronic splicing silencers) to increase exon 7 inclusion in SMN2 transcripts, increasing SMN protein production
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How are ASOs used to downregulate transcript translation

A
  • Suppress translation of HTT mRNA containing a pathological CAG repeat expansion in Huntington’s disease.
  • However, also targeted all CAG containing genes, not specifically HTT.
  • To improve specificity, targeted for HTT-dependent SNPs
  • e.g. IONIS-HTTRx
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the challenges of using ASOs

A
  • Delivery to target tissue
  • To achieve sustained effect. Re-administration required
  • Hard to completely inhibit process. Large quantities of mRNA compared to ASO
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is RNA interference (RNA i)

A

A cellular mechanism of post-transcriptional gene silencing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are siRNAs

A

small double stranded RNAs (20-25nt)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What enzyme catalyses the production of siRNAs

A

Dicer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How do siRNAs silence genes

A

-siRNAs are incorporated into the RNA induced silencing complex (RISC) which binds to mRNA and cleaves it.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Benefits of siRNA as a potential therapy

A
  • High sequence specificity

- Currently no RNAi-based therapeutics available

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Example of an isoform specific RNAi

A
  • VEGF has 5 alternatively spliced isoforms. VEGF165 is strongly implicated in tumour angiogenesis.
  • Silencing VEGF165 isoform can be done using RNAi that targets sequences at exons 5-7.
  • Benefits- other VEGF isoforms remain functional
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Example of an allele-specific RNAi

A
  • Designing siRNAs that can discriminate between wildtype and mutant alleles.
  • Could be used for dominant gain-of-function disorders, where mutated allele is targeted.
  • E.g. COL1A1 in Osteogenesis imperfecta. Targets common SNPs rather than designing for each rare mutation.
17
Q

Challenges of RNAi

A
  • Delivery. Virally expressed, lipid-based delivery agents, nanoparticle technology.
  • Non-specific off-target effects.
  • siRNAs likely to elicit immunological responses against vector components
18
Q

Describe CRISPR-Cas9 process

A
  • CRISPR (clustered regularly interspaced short palendromic repeats) are sequences play a role in the defense system of prokaryotes.
  • Cas9 (CRISPR-associated protein 9) an enzyme that uses CRISPR sequences as a guide to recognize and cleave specific strands of DNA that are complementary to the CRISPR sequence
  • Cost effective
  • Trials for beta thalassemia (CTX100)
19
Q

Issues with CRISPR-Cas9 / gene editing

A
  • Ethics of editing a genome
  • Delivery to target cells
  • Off target mutagenesis. Use of guide RNAs should reduce this.
20
Q

Examples of small molecules as therapeutics

A
  • Zinc finger: create artificial restriction enzymes by fusing a zinc finger to DNA-binding domain. Difficult to design and target sites are limited.
  • TALENS (Transcription activator-like effector nucleases). Artificial restriction enzymes made by fusing a TAL effector DNA-binding domain to a DNA cleavage domain. More specific but larger, so delivery is more challenging.
21
Q

Drugs that allow read-through of premature termination codons (PTCs)

A
  • 10% of human diseases are caused by nonsense mutations
  • Aminoglycoside antibiotics allow ribosomes to read through PTCs in mRNA, leading to production of full length protein.
  • Efficiency varies due to neighbouring sequence, drug, nature of PTC.
  • Ataluren induces ribosomes to read through PTCs but not normal stop codons. Targets mRNAs, so a problem if patient has low mRNA levels. Used for DMD, CF in phase III trials.
22
Q

Molecules that promote correct folding/transport/alter activation

A
  • Ivacaftor= improves transport of chloride through ion channels in patients that carry Gly551Asp.
  • Lumacaftor enhances correct folding of Phe508del so it can reach cell membrane